Dr. Chiara Cremolini on the Updated Results of the TRIBE2 Study for Unresectable Colorectal Cancer
Cancer Network spoke with Chiara Cremolini, MD, about the updated results of the phase III randomized strategy study TRIBE2, which looked at the first- and second-line treatment of unresectable metastatic colorectal cancer.
Cancer Network spoke with Chiara Cremolini, MD, of Azienda Ospedaliero-Universitaria Pisana, about the updated results of the phase III randomized strategy study TRIBE2, which looked at the first- and second-line treatment of unresectable metastatic colorectal cancer.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
